

AACC 2021 CLFS Recommendations

Code	Code Description	AACC Crosswalk Recommendation	Rationale	Proposed NLA
Reconsideration				
81307	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence	81317	The work and resources align with the number of exons studied in the PALB2 gene analysis, full gene sequence.	\$676.50
Molecular Pathology Tier 1				
8XX00	SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L)	81120	The methodology, resources, and amount of genetic material sequenced are comparable to that of IDH1 common variants. Both assess genes for an oncology disorder and similar number of variants.	\$193.25
8XX01	SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L)	81233	The methodology, resources, and amount of genetic material sequenced are comparable to that of BTK common variants. Both assess genes for an oncology disorder and similar number of variants.	\$175.40
8XX02	U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P)	81120	The methodology, resources, and amount of genetic material sequenced are comparable to that of IDH1 common variants. Both assess genes for an oncology disorder and similar number of variants.	\$193.25
8XX03	ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	81120	The methodology, resources, and amount of genetic material sequenced are comparable to that of IDH1 common variants. Both assess genes for an oncology disorder and similar number of variants.	\$193.25
8X000	NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis	81315	The methodology, resources, and amount of genetic material sequenced are comparable to that of PML/RARalpha translocation analysis	\$207.31
8X001	NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis	81315	The methodology, resources, and amount of genetic material sequenced are comparable to that of PML/RARalpha translocation analysis.	\$207.31
8X002	NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis	81315	The methodology, resources, and amount of genetic material sequenced are comparable to that of PML/RARalpha translocation analysis.	\$207.31

8X020	NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis	81315 X 2.5	The methodology, resources, and amount of genetic material sequenced are comparable to that of 81315 X 2.5	\$207.31 X 2.5 = \$518.26
8X003	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence	81298	The methodology, resources, and amount of genetic material sequenced are comparable to that of MSH6 full sequence analysis. Both assess germline cancer disposition genes and are relatively the same size.	\$641.85
8X004	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology)	81334	The methodology, resources, and amount of genetic material sequenced are comparable to that of MSH6 known familial variants. Both assess targeted sequences in cancer-related genes.	\$329.51
8X005	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant	81299	The methodology, resources, and amount of genetic material sequenced are comparable to that of MSH6 known familial variants. Both assess known familial variants in germline cancer disposition	\$308.00
8X006	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R)	81120	The methodology, resources, and amount of genetic material sequenced are comparable to that of IDH1 common variants (81120)	\$193.25
8X007	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10	81310	The methodology, resources, and amount of genetic material sequenced are comparable to that of NPM1 gene analysis (81310)	\$246.52
8X008	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)	81272	The methodology, resources, and amount of genetic material sequenced are comparable to that of KIT targeted sequence analysis.	\$329.51
8X009	IGH@/BCL2(t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative	81315	The methodology, resources, and amount of genetic material sequenced are comparable to that of translocation analysis for PML-RARA	\$207.31
8X010	CCND1/IGH(t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed	81315	The methodology, resources, and amount of genetic material sequenced are comparable to that of translocation analysis for PML-RARA	\$207.31
Microbiology				

87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	87502	This code represents similar methodology and resources to perform the testing.	\$95.80
Immunology				
86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	86794 X 2.5	Qualitative or semiquantitative immunoassays for Zika virus IgM	\$16.85 X 2.5 = \$42.13
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	86794 x 2.5	Qualitative or semiquantitative immunoassays for Zika virus IgM	\$16.85 X 2.5 = \$42.13
Chemistry				
81XX3	Alcohol (ethanol); any specimen except urine and breath, immunoassay (eg, IA, EIA, ELISA, RIA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)	83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified represents the methodology being used for the assay. Similar resources required to perform assay.	\$17.27
82XX1	Estradiol; free, direct measurement (eg, equilibrium dialysis)	82670	Current coding is 82670. This code represents similar methodology and resources to perform the testing.	\$27.94
Therapeutic Drug Assay				
80XXX	Acetaminophen	80299	This code represents similar methodology and resources to perform the testing.	\$18.64
80XX2	Amiodarone	80155	This code represents similar methodology and resources to perform the testing.	\$38.57
80XX1	Salicylate	80299	This code represents similar methodology and resources to perform the testing.	\$18.64

80XX3	Carbamazepine; 10,11-Epoxyde	80155	This code represents similar methodology and resources to perform the testing.	\$38.57
80XX4	Felbamate	80199	This code represents similar methodology and resources to perform the testing and is used to treat seizures/epilepsy .	\$27.11
80XX5	Flecainide	80155	This code represents similar methodology and resources to perform the testing.	\$38.57
80XX6	Itraconazole	80187	This code represents similar methodology and resources to perform the testing and is used to treat antifungal infections.	\$27.11
80XX7	Leflunomide	80230	This code represents similar methodology and resources to perform the testing and is used for inflammatory disorders.	\$38.57
80XX8	Methotrexate	80230	This code represents similar methodology and resources to perform the testing and is used for inflammatory disorders.	\$38.57
802XX	Rufinamide	80199	This code represents similar methodology and resources to perform the testing and is used to treat seizures/epilepsy.	\$27.11

